CY2422B1 - Human cancer antigen of tyrosinase-related protein1 and 2 and genes encoding same. - Google Patents

Human cancer antigen of tyrosinase-related protein1 and 2 and genes encoding same.

Info

Publication number
CY2422B1
CY2422B1 CY0400007A CY0400007A CY2422B1 CY 2422 B1 CY2422 B1 CY 2422B1 CY 0400007 A CY0400007 A CY 0400007A CY 0400007 A CY0400007 A CY 0400007A CY 2422 B1 CY2422 B1 CY 2422B1
Authority
CY
Cyprus
Prior art keywords
recognized
antigen
cancer
peptide
derived
Prior art date
Application number
CY0400007A
Other languages
English (en)
Inventor
Rong-Fu Wang
Steven A Rosenberg
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of CY2422B1 publication Critical patent/CY2422B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CY0400007A 1996-02-09 2004-01-13 Human cancer antigen of tyrosinase-related protein1 and 2 and genes encoding same. CY2422B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/599,602 US5840839A (en) 1996-02-09 1996-02-09 Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US08/725,736 US5831016A (en) 1996-02-09 1996-10-04 Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

Publications (1)

Publication Number Publication Date
CY2422B1 true CY2422B1 (en) 2004-11-12

Family

ID=24400301

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400007A CY2422B1 (en) 1996-02-09 2004-01-13 Human cancer antigen of tyrosinase-related protein1 and 2 and genes encoding same.

Country Status (12)

Country Link
US (4) US5840839A (xx)
EP (3) EP1092770A3 (xx)
JP (1) JP3998713B2 (xx)
AT (2) ATE251670T1 (xx)
AU (1) AU729497B2 (xx)
CA (2) CA2733866C (xx)
CY (1) CY2422B1 (xx)
DE (2) DE69738630T2 (xx)
DK (2) DK1411124T3 (xx)
ES (2) ES2305379T3 (xx)
PT (2) PT1411124E (xx)
WO (1) WO1997029195A2 (xx)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08500740A (ja) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6297253B1 (en) * 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7335351B2 (en) * 1997-03-19 2008-02-26 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
ATE252596T1 (de) * 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6043084A (en) * 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
EP1021535B1 (en) * 1997-10-08 2007-03-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen ny eso-1/cag-3 and gene encoding same
EP1806403A3 (en) * 1997-10-08 2008-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
US7084239B1 (en) * 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
WO1999024566A1 (en) * 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
JP3559894B2 (ja) 1998-04-01 2004-09-02 日産自動車株式会社 樹脂製ウィンドウ及びその製法
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
WO1999065522A1 (en) * 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
ATE375362T1 (de) * 1998-06-25 2007-10-15 Kyogo Itoh Von cyclophilin b abstammende tumorantigen- peptide
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
KR100767554B1 (ko) * 1998-07-31 2007-10-17 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
EP1109568A4 (en) * 1998-09-04 2002-05-08 Ludwig Inst Cancer Res ANTIGENIC PEPTIDE ENCODED BY ANOTHER OPEN READING FRAMEWORK THAT STIMULATES THE PROLIFERATION OF MACROPHAGES
AU1598500A (en) * 1998-10-26 2000-05-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
AU756398B2 (en) * 1999-03-11 2003-01-09 Smithkline Beecham Biologicals (Sa) Novel compounds
US6389376B1 (en) * 1999-07-26 2002-05-14 Sun Microsystems, Inc. Method and apparatus for generating n-segment steiner trees
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
US7795379B2 (en) * 1999-11-30 2010-09-14 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US6774226B1 (en) * 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP2311950A1 (en) * 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
CA2410865A1 (en) * 2000-05-31 2001-12-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
ES2304398T3 (es) * 2000-07-31 2008-10-16 Green Peptide Co., Ltd. Antigeno de tumores.
AU8330401A (en) * 2000-08-11 2002-02-25 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP4503801B2 (ja) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 新規ヒト癌・精巣抗原及びその遺伝子
WO2002042325A2 (en) * 2000-10-31 2002-05-30 Zycos Inc. Cyp1b1 nucleic acids and methods of use
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
JP2005500247A (ja) * 2000-12-07 2005-01-06 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム ヒトｍｄａ−７に関わる処置方法
DE10061299A1 (de) * 2000-12-08 2002-06-27 Siemens Ag Vorrichtung zur Feststellung und/oder Weiterleitung zumindest eines Umwelteinflusses, Herstellungsverfahren und Verwendung dazu
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
WO2002068653A2 (en) * 2001-02-26 2002-09-06 Imclone Systems Incorporated Tri-hybrid melanoma antigen
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
AU2002307438A1 (en) * 2001-04-20 2002-11-05 Ludwig Institute For Cancer Research Cancer-testis antigens
EP1401472A4 (en) * 2001-05-25 2005-04-06 Univ Jefferson ALTERNATIVE SHAPING FORMS OF PROTEINS AS THE BASIS FOR MULTIPLE THERAPEUTIC MODALITIES
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
AU2002327614B2 (en) * 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
US7202045B2 (en) 2001-09-19 2007-04-10 Regents Of The University Of Michigan Detection and treatment of cancers of the lung
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
US20030148285A1 (en) * 2001-12-20 2003-08-07 Claude Perreault Mammalian SIMP protein, gene sequence and uses thereof in cancer therapy
JP4376629B2 (ja) * 2002-01-08 2009-12-02 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2482477A1 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
DE10221411B4 (de) * 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
DK1585812T3 (en) * 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
US7404950B2 (en) 2003-02-18 2008-07-29 Baylor College Of Medicine Induced activation in dendritic cell
WO2004111075A2 (en) * 2003-03-05 2004-12-23 Dendreon Corporation Alternative reading frame polypeptides for treatment
CA2518546C (en) * 2003-03-20 2012-11-13 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
WO2005010035A2 (en) * 2003-07-22 2005-02-03 Branch Andrea D Alternate reading frame polypeptides derived from hepatitis c and methods of their use
DE602004031116D1 (de) * 2003-07-22 2011-03-03 Ludwig Inst For Cancer Res New York Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide
EP1677773A1 (en) * 2003-10-14 2006-07-12 Biomira, Inc. Combination therapy for cancer
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
EP2186896B1 (en) * 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
ES2321212T3 (es) * 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006086798A2 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
SG162817A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ564360A (en) * 2005-06-17 2011-03-31 Mannkind Corp Immunogenic product comprising a nucleic acid capable of expressing a PRAME epitope and a PSMA epitope and a peptide composition
TWI511738B (zh) 2005-06-28 2015-12-11 Oncothyreon Inc 以黏液性糖蛋白(ｍｕｃ-１）疫苗治療病人之方法
US8674059B2 (en) * 2005-07-27 2014-03-18 Oncotherapy Science, Inc. Colon cancer related gene TOM34
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
WO2007053956A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
CN101365473B (zh) * 2005-11-16 2013-04-03 潘塔希生物科学股份有限公司 用于治疗或预防卵巢癌的药物组合物
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) * 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2007310946B2 (en) 2006-10-19 2014-06-05 Baylor College Of Medicine Generating an immune response by inducing CD40 and pattern recognition receptors
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
NZ587305A (en) 2008-03-12 2012-05-25 Imclone Llc Anti-tyrosinase-realted protein-1 (TYRP1) antibodies
WO2009149094A2 (en) * 2008-06-02 2009-12-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
EP2296696B1 (en) 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US9068020B2 (en) * 2008-09-02 2015-06-30 Cedars-Sinai Medical Center CD133 epitopes
US20100203067A1 (en) * 2008-09-22 2010-08-12 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US10383924B2 (en) 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR102004900B1 (ko) 2010-12-02 2019-07-29 온코세라피 사이언스 가부시키가이샤 Tomm34 펩티드 및 이를 포함한 백신
WO2012116225A2 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
CN104685360B (zh) 2012-06-26 2018-02-13 比奥德希克斯股份有限公司 用于选择和去选择用产生免疫应答的疗法治疗的癌症患者的质谱方法
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9861688B2 (en) 2012-12-14 2018-01-09 Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz T cell receptors with MHC independent binding to GM-CSF receptor alpha chain
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
US11419925B2 (en) * 2013-03-15 2022-08-23 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
EP2978444B1 (en) 2013-03-28 2018-12-05 Invectys A cancer vaccine for dogs
AU2014242915B2 (en) 2013-03-28 2018-08-09 Invectys A cancer vaccine for cats
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
AU2014343813B2 (en) 2013-10-28 2020-02-27 Invectys A telomerase encoding DNA vaccine
DK3063280T3 (da) 2013-10-28 2019-11-11 Invectys Genelektrooverførsel ind i hudceller
WO2015063616A2 (en) 2013-11-04 2015-05-07 Uti Limited Partnership Methods and compositions for sustained immunotherapy
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
HUE056414T2 (hu) * 2014-09-17 2022-02-28 Io Biotech Aps Triptofán-2,3-dioxigenázt vagy annak fragmentumait tartalmazó vakcinakészítmények
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CA2973771A1 (en) * 2015-01-16 2016-07-21 Minomic International Ltd. Glypican epitopes and uses thereof
JP6028253B2 (ja) * 2015-01-28 2016-11-16 学校法人北里研究所 癌細胞の検出方法及び癌細胞検出キット
CA2978171A1 (en) 2015-03-10 2016-09-15 J.H. Frederik Falkenburg T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
AU2016275312B2 (en) 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
CA3056212A1 (en) * 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
EP3622078A1 (en) 2017-05-09 2020-03-18 Invectys Recombinant measles vaccine expressing htert
US20210147507A1 (en) 2017-05-09 2021-05-20 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
CA3065325A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
JP2021505139A (ja) 2017-12-08 2021-02-18 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｃａｒ−ｔ細胞の効力を増強及び維持するための方法
CN109293739B (zh) * 2018-01-24 2021-03-30 中国疾病预防控制中心病毒病预防控制所 一种a3超家族通用肿瘤抗原多肽及其应用
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
EP3793576A4 (en) 2018-05-15 2022-04-06 Globeimmune, Inc. RECOMBINANT YEAST LYSATES FOR INDUCING CELLULAR IMMUNE RESPONSE
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910820A1 (en) * 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
WO1994002626A1 (en) * 1992-07-20 1994-02-03 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation

Also Published As

Publication number Publication date
WO1997029195A3 (en) 1997-11-13
DK0882130T5 (da) 2004-05-17
CA2245702A1 (en) 1997-08-14
US5831016A (en) 1998-11-03
US5840839A (en) 1998-11-24
DE69725428D1 (de) 2003-11-13
PT1411124E (pt) 2008-07-04
EP1411124A2 (en) 2004-04-21
PT882130E (pt) 2004-02-27
ATE251670T1 (de) 2003-10-15
CA2733866C (en) 2015-01-27
DK0882130T3 (da) 2004-03-08
JP2000506380A (ja) 2000-05-30
ES2206685T3 (es) 2004-05-16
EP0882130B1 (en) 2003-10-08
ATE391780T1 (de) 2008-04-15
AU1957297A (en) 1997-08-28
EP1092770A2 (en) 2001-04-18
EP1411124A3 (en) 2004-09-29
DE69738630T2 (de) 2009-05-07
EP1411124B1 (en) 2008-04-09
CA2245702C (en) 2011-10-04
EP1092770A3 (en) 2003-06-04
JP3998713B2 (ja) 2007-10-31
DK1411124T3 (da) 2008-08-04
DE69725428T2 (de) 2004-07-29
CA2733866A1 (en) 1997-08-14
ES2305379T3 (es) 2008-11-01
EP0882130A2 (en) 1998-12-09
DE69738630D1 (de) 2008-05-21
AU729497B2 (en) 2001-02-01
WO1997029195A2 (en) 1997-08-14
US6087110A (en) 2000-07-11
US6132980A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
CY2422B1 (en) Human cancer antigen of tyrosinase-related protein1 and 2 and genes encoding same.
DK0932678T3 (da) En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåde til anvendelse deraf
EP1439230A3 (en) Human transmembrane protein TMP-2 gene
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
AU9572098A (en) Novel human cancer antigen ny eso-1/cag-3 and gene encoding same
ES8802160A1 (es) Un procedimiento para aislar un gen de relaxina cromosomica de un ser humano o de otro primate o una especie afin
CA2175332A1 (en) Haemophilus transferrin receptor genes
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO2000020447A8 (en) Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
IE20000918A1 (en) GP75 As a Tumor Vaccine for Melanoma
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
EP1277837A3 (de) Epididymis-spezifische DNA-Sequenzen und deren Verwendung
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
MY127669A (en) Polypeptide hormone phosphatonin
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
EP0787798A3 (en) GRP17 gene
Fillat et al. OVEREXPRESSION OF FROM FERREDOXIN-NADP+ REDUCTASE Anabaena sp. PCC 7119 IN E. coli.
Niewold et al. Equine light-chain-associated amyloidosis
WO2000071567A3 (en) Fibroblast growth factor 13
EP1806403A3 (en) Human cancer antigen NY ESO 1/CAG-3 and gene encoding same